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background: Epidemiological studies suggest an inverse relationship between HDL-C levels and major adverse cardiovascular events (MACE), yet 
controversy exists regarding possible benefits of raising HDL-C in patients treated to low LDL-C levels (<70 mg/dL) with statins.
methods:In 7 serial coronary intravascular ultrasound trials, 3469 statin-treated patients with coronary disease were stratified according to 
achieved LDL-C (< or ≥70 mg/dL) and changes in HDL-C (≥ vs. < median) (Table). Changes in coronary percent atheroma volume (PAV) and MACE 
(cardiovascular death, non-fatal MI, stroke, coronary revascularization, hospitalization for unstable angina) were evaluated across these groups.
results: Overall, the median change in HDL-C was +6.03%, and the mean LDL-C across the LDL-C stratified groups was 55.2±11 and 97.4±22 
mg/dL. In patients with achieved LDL-C <70 mg/dL, greater HDL raising did not associate with disease regression [OR 1.10 (95% CI 0.86, 1.42), 
p=0.44] or lower MACE [HR 1.26 (95% CI 0.93, 1.49), p=0.11]. In those with achieved LDL-C ≥70 mg/dL, greater HDL raising was associated with 
less disease progression [OR 0.76 (95% CI 0.52, 0.96), p=0.018] and lower MACE [HR 0.75 (95% CI 0.47, 0.98), p=0.032] (Table).
conclusions: During statin therapy, raising HDL-C appears beneficial in patients with achieved LDL-C levels ≥70 mg/dL, but not with levels <70 
mg/dL. These findings outline the need for additional therapeutic strategies for reducing residual risk in those with LDL-C <70 mg/dL.
Table
PARAMETER On-treatment LDL-C <70 mg/dL On-treatment LDL-C ≥70/dL
∆HDL-C ≥6.03%
N=572
∆HDL-C <6.03%
N=571
∆HDL-C ≥6.03%
N=1162
∆HDL-C <6.03%
N=1164
LDL-C (mg/dL) 55.9±10 54.4±11 98.0±23 96.8±22
HDL-C (mg/dL) 49.2±12 43.3±11 47.1±11 43.4±11
Unadjusted analyses
On-treatment LDL-C <70 mg/dL
% ∆HDL-C ≥ vs. < 6.03%
P-value
On-treatment LDL-C ≥70 mg/dL
% ∆HDL-C ≥ vs. <6.03%
P-value
Change in PAV (%) -0.18±0.31 vs. 0.19±0.31 0.04 0.25±0.30 vs. 0.55±0.30 0.02
MACE (%) 11.4 vs. 11.4 0.93 17.0 vs. 22.1 0.002
Adjusted analyses
IVUS Progression vs. Regression
Adjusted OR (95% CI)
1.10 (0.86, 1.42) 0.44 0.76 (0.52, 0.96) 0.018
MACE
Adjusted HR (95% CI)
1.26 (0.93, 1.49) 0.11 0.75 (0.47, 0.98) 0.032
